Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year.
The Series C round of funding was led by Biotechnology Value Fund and Redmile Group.
The cellular process of breaking down proteins for reuse is called protein degradation. This system works by affixing an old or damaged protein with a tag, so it’s recognized by the proteasome, the cell’s recycling machinery…. Read more »
UNDERWRITERS AND PARTNERS
